Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018.
Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO Olivier Brandicourt will become chairman-elect, and Astellas Americas president James Robinson will assume the board treasurer’s role when Bradway takes the reins as PhRMA chairman.
“Now, more than ever, PhRMA member companies are bringing forth an unprecedented series of medical innovations to support human health. Our innovations promise to not only improve and extend the lives of millions of patients, but also to positively bend the cost curve by decreasing the financial burden of serious diseases on society,” Bradway said in a statement. “I look forward to working together with stakeholders across the health care continuum to ensure a fertile environment for innovation and to encourage creative policy positions so that patients have access to the medicines they need.”
Bradway has served as Amgen chairman since 2013 and as the company’s CEO since 2012. He joined Amgen in 2006 and served as president and chief operating officer before becoming CEO.
“I am pleased to welcome Bob to the board as our chairman-elect,” PhRMA president and CEO Stephen Ubl commented. “Our companies are developing therapies unimaginable just a decade ago, and these advances will help many patients with serious and debilitating diseases. Together, we will ensure this innovation continues by advancing a comprehensive set of market-based reforms that improve access and affordability for patients.”
The PhRMA board also acknowledged the leadership and contributions of Novartis CEO Joseph Jimenez, who served as chairman-elect and announced his retirement from the company effective in January 2018.